Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

13.49
-0.8600-5.99%
Post-market: 13.490.00000.00%16:05 EDT
Volume:2.27M
Turnover:30.86M
Market Cap:1.20B
PE:-3.31
High:14.56
Open:14.50
Low:13.18
Close:14.35
Loading ...

Stock Track | Travere Therapeutics Surges 5% on Analyst Optimism Despite Mixed Earnings

Stock Track
·
01 Nov 2024

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
01 Nov 2024

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Takeda Pharmaceutical Company (TAK) and Voyager Therapeutics (VYGR)

TIPRANKS
·
01 Nov 2024

Travere Therapeutics (TVTX) Receives a Buy from Barclays

TIPRANKS
·
01 Nov 2024

Travere Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
01 Nov 2024

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry

Simply Wall St.
·
01 Nov 2024

Stock Track | Travere Therapeutics Plunges After Announcing $100M Stock Offering Despite Solid Q3 Results

Stock Track
·
31 Oct 2024

BRIEF-Travere Therapeutics Entered Amended & Restated Agreement Of Upto $100 Million In Common Stock Offering

Reuters
·
31 Oct 2024

Travere Therapeutics: Entered Amended & Restated Agreement of Upto $100 Mln in Common Stock Offering

THOMSON REUTERS
·
31 Oct 2024

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
31 Oct 2024

Travere Therapeutics Q3 2024 GAAP EPS $(0.70), Inline, Sales $62.90M Beat $59.70M Estimate

Benzinga
·
31 Oct 2024

Travere Therapeutics Reports Third Quarter 2024 Financial Results

THOMSON REUTERS
·
31 Oct 2024

Travere Therapeutics Q3 Operating Income USD -56.149 Million VS. Ibes Estimate USD -53.3 Million

THOMSON REUTERS
·
31 Oct 2024

Travere Therapeutics Q3 Operating Expenses USD 119.047 Million

THOMSON REUTERS
·
31 Oct 2024

Travere Therapeutics Q3 EPS USD -0.7 VS. Ibes Estimate USD -0.66

THOMSON REUTERS
·
31 Oct 2024

J.P. Morgan Keeps Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
29 Oct 2024

Travere presents data reinforcing clinical benefit of FILSPARI in IgAN

TIPRANKS
·
27 Oct 2024

Travere Therapeutics Inc: Interim Data From Spartacus Study Demonstrated That Filspari, When Added to Stable Sglt2i, Was Generally Well Tolerated

THOMSON REUTERS
·
26 Oct 2024

Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'

Benzinga
·
25 Oct 2024

Travere Therapeutics to Report Third Quarter 2024 Financial Results

GlobeNewswire
·
22 Oct 2024